TABLE 3.

Means and standard deviations of each self-report measure at baseline, posttreatment, 6- and 12-week follow-ups, and effect sizes at posttreatment and 12-week follow-up.

	Baseline	Post	6-week F-U	12-week F-U	d-statistic for SCED Post treatment		d-statistic for SCED 12-w F-U
	M (SD)	M (SD)	M (SD)	M (SD)	d (SE)	95% CI	d (SE)	95% CI
Primary outcomes
DASS-Total: Emotional symptoms	37.17 (6.94)	12.17 (6.37)	7.17 (3.60)	5.83 (5.04)	2.16 (0.47)	[1.3, 3.1]	3.34 (0.76)	[2.0, 4.9]
DASS – Depression	13.60 (4.06)	5.33 (2.94)	2.50 (2.07)	2.00 (2.53)	1.45 (0.40)	[0.8, 2.3]	2.37 (0.78)	[1.1, 4.0]
DASS – Anxiety	9.67 (3.70)	1.83 (2.32)	1.00 (1.10)	1.17 (1.47)	1.47 (0.43)	[0.7, 2.3]	1.90 (0.62)	[0.9, 3.2]
DASS – Stress	13.90 (2.28)	5.00 (2.83)	3.67 (2.07)	2.67 (2.50)	2.28 (0.50)	[1.4, 3.3]	3.49 (0.74)	[2.2, 5.0]
PSWQ: Pathological worry	45.17 (3.49)	31.83 (8.33)	28.00 (8.56)	24.67 (7.47)	2.69 (0.95)	[1.0, 4.6]	4.52 (0.98)	[2.8, 6.6]
Secondary outcomes (process measures)
AAQ-II: Experiential avoidance	37.57 (4.71)	21.83 (6.55)	18.67 (9.07)	17.17 (10.26)	2.06 (0.67)	[0.9, 3.4]	3.46 (0.80)	[2.1, 5.1]
CFQ: Cognitive fusion	39.87 (4.10)	23.33 (8.82)	18.33 (8.69)	16.67 (11.18)	2.32 (0.60)	[1.3, 3.6]	3.90 (0.91)	[2.3, 5.8]
PTQ: Perseverative thinking	46.37 (4.01)	25.67 (11.59)	19.33 (9.48)	17.83 (8.80)	3.27 (0.91)	[1.6, 5.1]	4.52 (0.90)	[3.0, 6.4]
VQ: Valued living – Progress	13.50 (7.03)	22.17 (3.82)	19.00 (6.81)	21.67 (4.13)	0.99 (0.33)	[0.5, 1.7]	0.92 (0.51)	[0.1, 0.9]
VQ: Valued living – Obstruction	18.63 (3.31)	11.17 (2.56)	9.33 (2.58)	7.17 (5.27)	1.44 (0.34)	[0.8, 2.1]	1.98 (0.49)	[1.1, 3.0]

AAQ-II = Acceptance and Action Questionnaire – II; CFQ = Cognitive Fusion Questionnaire; DASS = Depression, Anxiety, and Stress Scales – 21; PSWQ = Penn State Worry Questionnaire; PTQ = Perseverative Thinking Questionnaire; SCED = Single-case experimental design; VQ = Valuing Questionnaire.